FDA Approves Amivantamab-Vmjw For EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer Indications For Adult Patients With Locally Advanced/ Metastatic NSCLC With EGFR Exon 20 Insertion Mutations; Recommended Dose Is Based On Body Weight
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Amivantamab-Vmjw for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that have EGFR Exon 20 insertion mutations. The recommended dose of Amivantamab-Vmjw is based on the patient's body weight.
March 01, 2024 | 7:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson, through its pharmaceutical division, has received FDA approval for Amivantamab-Vmjw, a treatment for EGFR Exon 20 insertion-mutated non-small cell lung cancer in adults.
The FDA approval of Amivantamab-Vmjw represents a significant advancement in the treatment of a specific form of lung cancer, potentially leading to increased demand for the drug. This approval could positively impact Johnson & Johnson's stock in the short term as it opens up a new revenue stream and strengthens its position in the oncology market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90